MONTREAL, QUEBEC--(Marketwire - February 06, 2008) - Theratechnologies (TSX: TH) announced today that new data from its first 52-week Phase 3 study testing tesamorelin in HIV-associated lipodystrophy were presented as a poster (Poster Number 943) on February 4, 2008 at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, Massachusetts.
